Evidence map›Paper›PMID 37470410›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

Discovery of 3-((3-amino-

Ashraf K El-Damasy, Hyun Ji Kim, Jung Woo Park, Yunju Nam, Wooyoung Hur, Eun-Kyoung Bang, Gyochang Keum

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Ashraf K El-DamasyBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Hyun Ji KimBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Jung Woo ParkSupercomputing Application Center, Div. of National Supercomputing, Korea Institute of Science and Technology Information, Daejeon, Republic of Korea.
Yunju NamMedicinal Materials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Wooyoung HurMedicinal Materials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Eun-Kyoung BangBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Gyochang KeumBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Korea Institute of Science and Technology · KRKorea Institute of Brain Science · KRKorea Institute of Science & Technology Information · KRKorean Association Of Science and Technology Studies · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BCR-ABL inhibition is an effective therapeutic approach for the treatment of chronic myeloid leukaemia (CML). Herein, we report the discovery of

Indexed as

IndazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveApoptosisBenzamidesCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansImatinib MesylateMutationProtein Kinase InhibitorsbenzamideBenzamidesFusion Proteins, bcr-ablImatinib MesylateIndazolesProtein Kinase InhibitorsABLT315IaminoindazoleChronic myeloid leukaemiadiarylamidesImatinib resistance

Identifiers

PMID37470410
PMCPMC10360995
OpenAlexW4384820170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.